Long-Term Cardiovascular Safety of Melatonin: Why Dose, Duration, and Patient Phenotype Matter
Authors:
- Esteban Zavaleta-MonestelEZEsteban Zavaleta-Monestel
- José A Castro GamboaJGJosé A Castro Gamboa
- Kevin Cruz MoraKMKevin Cruz Mora
- Jeaustin Mora-JiménezJMJeaustin Mora-Jiménez
Open Access
- 3 November 2026
- journal article
- Published by Springer Nature in Cureus
- Vol. 18 (11)
Abstract
The long-term cardiovascular safety of melatonin remains an important area of clinical uncertainty. This editorial examines the challenges involved in evaluating cardiovascular risk associated with prolonged melatonin exposure, emphasizing the importance of dose, treatment duration, formulation, product quality, and patient characteristics. Particular attention is given to methodological limitations that complicate the interpretation of observational associations, including residual confounding, reverse causation, and exposure misclassification. The discussion also considers potential biological mechanisms while distinguishing mechanistic hypotheses from established causal relationships. A more comprehensive approach to cardiovascular safety assessment is proposed, incorporating precise exposure characterization, clinically relevant cardiovascular outcomes, and patient phenotyping. Future research should integrate these factors through appropriately designed clinical trials and observational studies to clarify the cardiovascular implications of long-term melatonin use. Until stronger evidence becomes available, clinical interpretation should acknowledge the remaining uncertainty rather than assuming either cardiovascular safety or harm.Keywords
This publication has 17 references indexed in Scilit:
- Association between insomnia symptoms and risk of heart failure: A meta-analysis of prospective cohort studiesJournal of Cardiology, 2025
- Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studiesThe Lancet Diabetes & Endocrinology, 2024
- Investigating the safety profiles of exogenous melatonin and associated adverse events: A pharmacovigilance study using WHO‐VigiBaseJournal of Pineal Research, 2024
- Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US2023
- Adverse events in long-term studies of exogenous melatoninExpert Opinion on Drug Safety, 2022
- Trends in Use of Melatonin Supplements Among US Adults, 1999-2018JAMA, 2022
- Insomnia as a predictor of recurrent cardiovascular events in patients with coronary heart diseaseSLEEP Advances, 2022
- Safety of higher doses of melatonin in adults: A systematic review and meta‐analysisJournal of Pineal Research, 2021
- The association of insomnia disorder characterised by objective short sleep duration with hypertension, diabetes and body mass index: A systematic review and meta-analysisSleep Medicine Reviews, 2021
- Worldwide and regional prevalence rates of co-occurrence of insomnia and insomnia symptoms with obstructive sleep apnea: A systematic review and meta-analysisSleep Medicine Reviews, 2019